-
Moderna CEO Sells Shares, Deletes Social Media: What You Need To Know
Monday, February 14, 2022 - 2:32pm | 300Read More...Moderna Inc (NASDAQ: MRNA) shares are down more than 40% since the start of the year and continue to trend lower Monday. Vaccine stocks are facing selling pressure as the COVID-19 omicron variant fades, but Moderna investors have been expressing concerns...
-
The Search For Silver Linings In The Cloud Of Negative Novavax News
Monday, September 19, 2016 - 11:35am | 497Read More...It’s hard to find a silver lining following news that sends a stock crashing 84.5 percent in one day. However, following devastating news that the Phase III RESOLVE trial of its RSV vaccine failed to deliver the desired results, Novavax, Inc. (NASDAQ: NVAX) shareholders are looking for any...
-
Reports: Medivation Has No Plans To Sell Itself
Wednesday, March 30, 2016 - 6:05pm | 328Read More...Medivation Inc (NASDAQ: MDVN) shares were trading sharply higher in Wednesday's after-hours session amid word of a new report from Bloomberg, saying the company is working with bankers to defend itself against preliminary interest of a takeover. Earlier this week, Citi analyst Yigal...
-
CNBC's Meg Tirrell Breaks Down The AbbVie/Express Scripts Deal
Tuesday, December 23, 2014 - 2:01pm | 400Read More...Express Scripts, the largest pharmacy benefit management organization in the United States, announced on Monday that it has exclusively selected AbbVie Inc's (NYSE: ABBV) new drug over Gilead Sciences, Inc.'s (NASDAQ: GILD) Hepatitis C drug. Following the announcement, the stock of Gilead...
-
Merck's CEO Doesn't Think That Valuations In The Biotech Industry Are 'Rich'
Monday, December 8, 2014 - 1:46pm | 310Read More...Merck & Co., Inc. (NYSE: MRK) announced that it has agreed to acquire Cubist Pharmaceuticals Inc (NASDAQ: CBST) for $9.5 billion. Although the deal and the price is great source of joy for Cubist shareholders, the same cannot be said for Merck shareholders as some analysts on the Streets...
-
A Technical Look At Biogen's Huge Rally
Wednesday, December 3, 2014 - 1:14pm | 536Read More...For investors that dabble in biotech stocks, it is common knowledge that these entities react to drug trial results and FDA approvals more so than on earnings announcements and ratings changes. There is no better better example of this occurring than in the price action of Biogen Idec Inc (...
-
Why Biogen Shares Soared Today
Tuesday, December 2, 2014 - 12:34pm | 432Read More...Shares of Biogen Idec Inc (NASDAQ: BIIB) opened strong Tuesday, making a high of $336.65, and have held up pretty well. The reason for this sudden uptick is the company announcing that its experimental Alzheimer's drug has shown promise in early studies. Jim Cramer recently discussed the...
